AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’

On January 5, 2023 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases – including COVID-19, the disease caused by the SARS-CoV-2 virus – reported that AIM Chief Executive Officer Thomas K. Equels will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023, at 11:00 AM ET (Press release, AIM ImmunoTech, JAN 5, 2023, View Source [SID1234625863]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live video webcast of the presentation will be available on the Events & Presentations page of the Company’s website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.